Has Cannabis Legalization Affected the Prevalence of Cannabis Use Among Youth?

A study opens in new tab/window in the Journal of the American Academy of Child and Adolescent Psychiatry opens in new tab/window ( opens in new tab/windowJAACAP opens in new tab/window) opens in new tab/window, published by Elsevier reports that the legalization of recreational cannabis in various states in the US has resulted in an increased likelihood of cannabis use in the past month among adolescents and young adults. Cannabis use for medical purposes has been legalized in 38 states, while 24 states have legalized cannabis for recreational purposes for those above 21 years of age. Previous meta-analytic studies have shown that legalization of cannabis for medical use did not have a significant effect on the prevalence of cannabis use in youth. However, the results regarding the effects of recreational cannabis laws have been inconclusive due to the small number of states with recreational cannabis laws included in prior meta-analyses. With an increasing number of states legalizing recreational cannabis, it has become imperative to assess the effect of legalization on youth cannabis use. Studying the effects of legalization of cannabis use can provide a basis to devise preventative measures aimed at reducing the risks associated with cannabis use on the developing brains of adolescents and young adults in the United States.

This meta-analytic review, led Dr. Aditya Pawar, identified 4,604 citations, of which the authors systematically reviewed and meta-analyzed thirty studies that provided quantitative data showing the effects of cannabis legalization amongst adolescents and young adults. Included studies mostly utilized large datasets from nationwide surveys, and had compared the past month cannabis use between states with and without cannabis legalization. The authors found that recreational cannabis legalization was associated with a significant increase in cannabis use, with the effect being more pronounced in young adults. Limiting the analysis to more recent studies also showed a small, but significant, increase in cannabis use amongst adolescents as well.

In discussing the findings of this meta-analysis, Dr. Pawar states, “Cannabis use, especially frequent and high-potency cannabis use can severely affect neurodevelopment among adolescents and early use increases the chances of dependent use among young adults. Increasing trends towards legalization can potentially decrease the perceived risk of harm leading to an increased cannabis use. Evidence base showing an increase in cannabis use among youth should help public and policy makers use preventative measures including but not limited to public education, devising appropriate regulations in the laws such as regarding the potency and availability of cannabis, and increasing availability of evidence based early interventions.” The authors conclude that this meta-analysis emphasizes the need to further assess the benefits and harms that cannabis legalization may have on the youth in the US considering an increase in youth cannabis use.

Notes for editors

The article is a "Systematic Review and Meta-Analysis: Medical and Recreational Cannabis Legalization and Cannabis Use Among Youth in the United States," by Aditya K.S. Pawar, MD, Elizabeth S. Firmin, BA, Timothy E. Wilens, MD, Christopher J. Hammond, MD, PhD. (https://doi.org/10.1016/j.jaac.2024.02.016). It appears in the Journal of the American Academy of Child & Adolescent Psychiatry, volume 63, issue 11 (November 2024), published by Elsevier opens in new tab/window.

Copies of this paper are available to credentialed journalists upon request; please contact Aditya K.S. Pawar, MD at [email protected].

About JAACAP

Journal of the American Academy of Child and Adolescent Psychiatry opens in new tab/window (JAACAP) is the official publication of the American Academy of Child and Adolescent Psychiatry. JAACAP is the leading journal focusing exclusively on today's psychiatric research and treatment of the child and adolescent. Published twelve times per year, each issue is committed to its mission of advancing the science of pediatric mental health and promoting the care of youth and their families.

The Journal's purpose is to advance research, clinical practice, and theory in child and adolescent psychiatry. It is interested in manuscripts from diverse viewpoints, including genetic, epidemiological, neurobiological, cognitive, behavioral, psychodynamic, social, cultural, and economic. Studies of diagnostic reliability and validity, psychotherapeutic and psychopharmacological treatment efficacy, and mental health services effectiveness are encouraged. The Journal also seeks to promote the well-being of children and families by publishing scholarly papers on such subjects as health policy, legislation, advocacy, culture and society, and service provision as they pertain to the mental health of children and families.

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation opens in new tab/window, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX opens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.